Esperion Therapeutics, Inc. — Net Income by Fiscal Year
16 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/39e3ebc9-96ab-4cb9-bd03-6a1044ab6eb4/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-22.7M | 2025-01-01 – 2025-12-31 | evidence 0001628280-26-016522 |
| FY 2024 | $-51.7M | 2024-01-01 – 2024-12-31 | evidence 0001628280-25-011154 |
| FY 2023 | $-209.2M | 2023-01-01 – 2023-12-31 | evidence 0001628280-24-007066 |
| FY 2022 | $-233.7M | 2022-01-01 – 2022-12-31 | evidence 0001628280-23-004167 |
| FY 2021 | $-269.1M | 2021-01-01 – 2021-12-31 | evidence 0001628280-22-003263 |
| FY 2020 | $-143.6M | 2020-01-01 – 2020-12-31 | evidence 0001628280-21-002865 |
| FY 2019 | $-97.2M | 2019-01-01 – 2019-12-31 | evidence 0001104659-20-026203 |
| FY 2018 | $-201.8M | 2018-01-01 – 2018-12-31 | evidence 0001047469-19-000791 |
| FY 2017 | $-167.0M | 2017-01-01 – 2017-12-31 | evidence 0001047469-18-000899 |
| FY 2016 | $-75.0M | 2016-01-01 – 2016-12-31 | evidence 0001047469-17-000831 |
| FY 2015 | $-49.8M | 2015-01-01 – 2015-12-31 | evidence 0001047469-16-010437 |
| FY 2014 | $-36.4M | 2014-01-01 – 2014-12-31 | evidence 0001047469-15-001908 |
| FY 2013 | $-75.9M | 2008-01-22 – 2014-03-31 | evidence 0001104659-14-037619 |
| FY 2012 | $-11.7M | 2012-01-01 – 2012-12-31 | evidence 0001047469-15-001908 |
| FY 2011 | $-10.8M | 2011-01-01 – 2011-12-31 | evidence 0001047469-14-002320 |
| FY 2010 | $-19.4M | 2008-01-22 – 2010-12-31 | evidence 0001047469-14-002320 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Esperion Therapeutics, Inc. — all facts · Revenue · Operating Income